Detalhe da pesquisa
1.
Combining Panitumumab With Anti-PD-1 Antibody in Cutaneous Squamous Cell Carcinoma of the Head and Neck After Inadequate Response to Anti-PD-1 Antibody Alone.
J Drugs Dermatol
; 20(8): 901-904, 2021 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34397194
2.
Early on-treatment assessment of T-cells, cytokines and tumor DNA with adaptively-dosed nivolumab + ipilimumab: final results from the phase 2 ADAPT-IT study.
Clin Cancer Res
; 2024 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38767650
3.
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.
JAMA Oncol
; 9(1): 128-134, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36326731
4.
Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).
J Clin Oncol
; 40(10): 1059-1067, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34928709
5.
Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma.
J Transl Med
; 8: 9, 2010 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-20109236
6.
Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer.
J Immunother Cancer
; 7(1): 235, 2019 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31481112
7.
Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAFV600E Mutated Papillary Thyroid Cancer: Two Case Reports.
Thyroid
; 27(9): 1201-1205, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28805135
8.
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.
J Clin Oncol
; 20(8): 2045-52, 2002 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-11956264
9.
Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
J Invest Dermatol
; 122(2): 400-5, 2004 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15009722
10.
Phase II evaluation of temozolomide in metastatic choroidal melanoma.
Melanoma Res
; 13(3): 303-6, 2003 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12777987
11.
Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma.
Melanoma Res
; 14(1): 63-6, 2004 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15091196
12.
Melanoma brain metastasis: overview of current management and emerging targeted therapies.
Expert Rev Neurother
; 12(10): 1207-15, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23082737
13.
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 67(4): 945-54, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20607239
14.
Chemotherapy, cytokines, and biochemotherapy for melanoma.
Cancer Chemother Biol Response Modif
; 22: 739-48, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-16110637
15.
Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics.
Mol Cancer Ther
; 9(10): 2844-52, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20724522
16.
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
J Thorac Oncol
; 4(8): 1002-9, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19633475
17.
A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.
Melanoma Res
; 19(1): 42-9, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19430405
18.
Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.
Melanoma Res
; 18(4): 241-5, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18626307
19.
Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
J Cutan Pathol
; 33(4): 280-5, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16630177
20.
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
Cancer
; 106(9): 2005-11, 2006 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16565971